Amorphis Pharma Development Spółka z Ograniczoną Odpowiedzialnością (KRS 0000760620, NIP 9542799406) is a Polish company, headquartered in Katowice, Śląskie voivodeship. AMORPHIS PHARMA DEVELOPMENT operates in: Manufacture of basic pharmaceutical products (PKD 21.10.Z). Industry: Pharmaceuticals. The company has been listed in the National Court Register since November 30, 2018. AMORPHIS PHARMA DEVELOPMENT's most recently reported net revenue was 64.1 K PLN for 2022. AMORPHIS PHARMA DEVELOPMENT's operations are currently suspended.
The company is currently suspended
Suspended since January 5, 2026
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Amorphis Pharma Development
Identity
- Name
- Amorphis Pharma Development Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- November 30, 2018
- Registry status as of
- February 13, 2026
- Latest entry
- February 13, 2026
- Founding act
- 28.11.2018R.
Articles of association history (3)
- November 28, 2018: 28.11.2018R.
- November 20, 2019: 20.11.2019R., REP. A NR 4263/19, NOTARIUSZ ROMANA GRUŚKOŚ, KANCELARIA NOTARIALNA GRUSKOŚ NOWAK S.C. W KRAKOWIE UCHYLONO CAŁĄ DOTYCHCZASOWĄ TREŚĆ UMOWY SPÓŁKI I PRZYJĘTO NOWĄ TREŚĆ UMOWY SPÓŁKI, STANOWIĄCĄ JEDNOCZEŚNIE NOWY TEKST JEDNOLITY UMOWY SPÓŁKI
- December 19, 2019: 19.12.2019R., REP. A NR 4794/2019, NOTARIUSZ MARTA NOWAK, KANCELARIA NOTARIALNA GRUSKOŚ NOWAK S.C W KRAKOWIE, ZMIENIONO PAR. 9.1 UMOWY SPÓŁKI
Activities
Main activity
21.10.ZManufacture of basic pharmaceutical products
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. BANKOWA, 12, 147, 40-007, KATOWICE, POLSKA
- Voivodeship
- ŚLĄSKIE
- District
- KATOWICE
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 50.2180, 19.0232approx.
Risk and payment profile - Amorphis Pharma Development
Credibility rating
5 / 100
Very poor credibility
Insolvency risk
suspended
Significant formal threat
Closure risk
80
/ 100
Extremely high risk
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/7 yrs
Board changes
0
0/7 yrs
PKD changes
0
0/7 yrs
Name changes
0
0/7 yrs
Data from 7 years of registry activity.
Credibility history
Payment reliability score from 2019–2022
Current: S (5/100)
Trend: stable (0.0 pts/year)
Spółka jest obecnie zawieszona – działalność operacyjna wstrzymana, wskaźnik wiarygodności odzwierciedla stan przed zawieszeniem.
Trade credit limit history
Standard limit from 2019–2022
Current: 26.7 K PLN
Safe: 4.7 K PLN
Operational status - Amorphis Pharma Development
Founded
November 30, 2018
7 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KATOWICE
ŚLĄSKIE
Primary PKD
21.10.Z
Manufacture of basic pharmaceutical products
Share capital
5.8 K PLN
117 shares total
Shareholders
5
shareholders
Board
1 person
Sup. board: 3
Filed years
2 years
2019–2022 · profitable: 1/2
Registry entries
25
latest: February 13, 2026
Risk signals
Revenue
64.1 K PLN
2022
Net profit
15.4 K PLN
2022
Assets
1.0 M PLN
2022
Equity
456.1 K PLN
2022
EBITDA
44.6 K PLN
2022
Valuation
0 PLN
suspended
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Amorphis Pharma Development.
No ratings
Related articles
News
Bioton 2025: record EBITDA of PLN 53.8 m and revenue of PLN 235.9 m, but still a PLN 16.4 m net loss
Warsaw-based Bioton S.A. (KRS 0000214072) - the only Polish manufacturer of biosynthetic human insulin - closed 2025 with revenue of PLN 235.9 m and EBITDA of PLN 53.82 m (margin 18.72%), but a net loss of around PLN -16.4 m keeps the company in the red. EBITDA improved 76% versus 2024 (PLN 30.6 m), driven by international expansion (Malaysia ~PLN 100 m a year) and a contract to produce the insulin analogue Glargine. Yifan Pharmaceutical controls 31.65% of capital indirectly.
News
Celon Pharma 2025: record PLN 244 m revenue, but net loss deepens to PLN 79.4 m - the 2026 outlook hinges on Salmex registration in China and the GLP-1 programme
Celon Pharma S.A. (KRS 0000437778, Kiełpin/Łomianki) closed 2025 with consolidated revenue of PLN 244.34 m (+17.9% YoY), EBITDA of PLN 21.42 m (+42%) and a deepened net loss of PLN -79.36 m (vs PLN -34.45 m a year earlier). The deeper loss reflects spending on the innovative GLP-1 segment. The generics segment grows (+15.3%) and represents 84.4% of revenue. Salmex registration in China is expected by end-2026. Maciej Wieczorek controls 58.8% of capital and 68.2% of voting rights through Glatton sp. z o.o.
